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ABSTRACT. The discovery of molecules that bind tightly 
and selectively to desired proteins continues to drive 
innovation at the interface of chemistry and biology. This 
paper describes the binding of human insulin by the syn-
thetic receptor cucurbit[7]uril (Q7) in vitro. Isothermal 
titration calorimetry and fluorescence spectroscopy ex-
periments show that Q7 binds to insulin with an equilibri-
um association constant of 1.5 x 106 M-1 and with 50-
100-fold selectivity versus proteins that are much larger 
but lack an N-terminal aromatic residue, and >1000-fold 
selectivity versus an insulin variant lacking the N-
terminal phenylalanine (Phe) residue. The crystal struc-
ture of the Q7•insulin complex shows that binding occurs 
at the N-terminal Phe residue and that the N-terminus 
unfolds to enable binding. These findings suggest that 
site-selective recognition is based on the properties in-
herent to a protein terminus, including the unique chemi-
cal epitope presented by the terminal residue and the 
greater freedom of the terminus to unfold, like the end of 
a ball of string, to accommodate binding. Insulin recogni-
tion was predicted accurately from studies on short pep-
tides and exemplifies an approach to protein recognition 
by targeting the terminus. 
Living systems present a highly complex array of molecu-
lar surfaces that vary in size, shape, polarity, organization 
and solvation, and yet each molecule finds its target desti-
nation with high fidelity. The weak intermolecular forces 
(e.g., coulombic, dispersive, and solvophobic) that direct 
these events are well understood in principle.1-3 In practice, 
however, the design of synthetic compounds to recognize 
desired protein targets presents persistent challenges en 
route to pharmaceuticals, medical diagnostics, and other 
tools for biochemistry and chemical biology. So-called “ra-
tional” approaches to this problem use detailed knowledge 
of the structure of a target to aid in the design of a comple-
mentary molecule.4-6 Although high-resolution structures are 
available for a number of protein targets, the precise struc-
ture of the surface of a protein and the surrounding solvent 
remains difficult to predict from the genetically encoded 
sequence of amino acids or from homology modeling. 
Therefore, general design principles for sequence-based 
recognition of folded proteins do not currently exist. By con-
trast, numerous groups have reported on the sequence-
specific recognition of short peptides in aqueous solution by 
synthetic receptors.7-17 Short peptides are more practical 
than proteins for structure-activity studies of molecular 
recognition because they are less expensive, are easier to 
modify, and in many cases their structures are predictably 
folded/unfolded. Therefore, strategies for translating known 
approaches of peptide recognition into protein recognition 
would be exceptionally valuable. Here we show that the 
synthetic receptor cucurbit[7]uril (Q7, Figure 1) binds to the 
N-terminal phenylalanine (Phe) of human insulin, and that 
this recognition enables Q7 to bind more tightly to insulin 
than to proteins lacking an N-terminal aromatic residue. 
Equilibrium binding studies and X-ray crystallography 
 
Figure 1.  Amino acid sequences of the insulins and model 
peptides used in this study, and the chemical formula of Q7. 
reveal the molecular basis for recognition and show how the 
properties of a protein terminus are well suited to site-
selective recognition. 
Q7 is the seven-membered macrocycle in the cucur-
bit[n]uril (Qn) family of water-soluble, synthetic receptors, 
which have gained importance for their capacity to bind 
small guests very tightly and selectively in aqueous solu-
tion.18-20 The nonpolar interior and carbonyl-lined portals of 
Qn receptors work in concert to bind organic cations by 
including the hydrophobic portion of the guest within the 
apolar cavity and stabilizing the cationic group(s) with the 
portal oxygens. This cooperation between cavity and portal 
has proved ideal for binding to short peptides with an N-
terminal phenylalanine (Phe), tryptophan (Trp), or tyrosine 
(Tyr), in a sequence-specific fashion.14-17,21 In focused 
structure-activity studies with Q7 and Q8,15,17 all peptides 
had a single aromatic group and an N-terminal ammonium 
group, but only those with an N-terminal aromatic residue, 
which fixes both groups in close proximity, were bound se-
lectively by Q7 and Q8. Therefore, the terminus provided a 
binding site that is structurally unique at the level of a sin-
gle-residue and thus known from the sequence of amino 
acids. On the basis of these studies we predicted that a Qn 
receptor should bind selectively to an N-terminal aromatic 
residue versus all other surface-exposed aromatic residues 
 on a folded protein and thus provide a mechanism for site-
specific protein recognition. In the present study, human 
insulin was identified as a desirable model on which to test 
this hypothesis because it has a rare Phe residue at the N-
terminus of its B-chain (i.e., PheB1), it has been thoroughly 
characterized, and it is stably folded under ambient condi-
tions.22 
Isothermal titration calorimetry (ITC) experiments revealed 
that Q7 binds to recombinant human insulin 1 in a 1:1 stoi-
chiometric ratio with an equilibrium association constant 
(Ka) value of 1.5 x 106 
 
Figure 2.  (a) Representative ITC data for the titration of Q7 to 
native human insulin 1.  The top plot of power versus time was 
integrated to yield the bottom plot of molar enthalpy versus the 
ratio of Q7:insulin. The gray data points in the bottom plot are 
for the analogous experiment on variant insulin 2, showing no 
measurable binding. (b) Bar plot of the equilibrium association 
constants of analytes 1 – 5  in complex with Q7. Error bars are 
standard deviations from at least three measurements. The ITC 
technique has a practical lower limit of 103 M-1. 
M-1 (Figure 2). Although we anticipated binding at the PheB1 
position, insulin also has on its surface two Phe and four Tyr 
residues, all of which are possible binding sites. The series 
of compounds 2-5 (Figure 1) was designed to probe the 
location of binding. Protein 2 is a variant of human insulin 
with glutamic acid (Glu) at positions B1 and B27 (i.e., GluB1, 
GluB27).23,24 Peptides 3-5 are models of the N-terminal Phe 
(3), non-terminal Phe (4), and non-terminal Tyr (5) residues 
on the surface of insulin.  
ITC measurements (Figure 2 and Supporting Information) 
showed no measurable binding of Q7 to variant insulin 2, 
which has no N-terminal Phe, and thus a decrease in asso-
ciation constant by more than three orders of magnitude 
compared to native insulin 1. This result makes a strong 
case for PheB1 as the site of binding. Positive control pep-
tide 3 (Ka = 2.8 x 106 M-1), which has an N-terminal Phe, 
binds to Q7 with similar affinity as native insulin 1. Peptides 
4 (2.2 x 104 M-1) and 5 (2.7 x 103 M-1) were bound less tight-
ly than peptide 3 by two and three orders of magnitude, 
respectively, showing that non-terminal Phe and Tyr resi-
dues are possible, albeit weak, sites of binding for Q7. 
Therefore, we were surprised that Q7 showed no measura-
ble affinity for variant insulin 2, which suggests that the two 
non-terminal Phe and four non-terminal Tyr residues on the 
surface of 2 are significantly less accessible to binding than 
the analogous residues in peptides 4 and 5. 
We sought structural evidence to support the ITC data 
and to explore a molecular basis for recognition. Toward 
this end, we determined the crystal structure of the Q7•1 
complex (Figure 3). The asymmetric unit of the crystal (Fig-
ure 3a) contains two insulin molecules (1a and 1b) and one 
molecule of Q7, which is associated with insulin 1a at the N-
terminus of the B chain. Akin to previously reported struc-
tures of Q8 in complex with Phe-Gly-Gly and Trp-Gly-Gly,15 
the Q7•insulin structure shows the aromatic sidechain of 
PheB1 included within the cavity of Q7. In addition, ValB2 and 
AsnB3 contribute weak stabilizing interactions by contacting 
atoms of the Q7 exterior. Overall, the binding of Q7 buries 
approx. 200 Å2 of insulin’s solvent-accessible surface ar-
ea.25 The presence of Q7-bound insulin 1a and unbound 
insulin 1b in the asymmetric unit of the crystal allows us to 
study perturbations to the structure of insulin upon binding 
to Q7. Overall, the structures of 1a and 1b are strikingly 
similar, with a root mean square deviation (RSMD) of 0.37 Å 
over 35 alpha carbons. The largest deviations are observed 
at the B1-B4 residues of 1a, which unfold from the surface 
of the protein to accommodate Q7 (Figure 3b).  
These results corroborate the calorimetric data and pro-
vide a structural basis for recognition at the N-terminus of 
the B chain of insulin. As observed with small peptides,15 
stable binding requires the simultaneous inclusion of the 
hydrophobic sidechain of PheB1 within the cavity of Q7 and 
interaction of the N-terminal ammonium group with the por-
tal oxygens of Q7. The PheB1 residue therefore presents a 
unique binding epitope comprising the aromatic sidechain 
and the N-terminal ammonium group, which cannot exist 
anywhere else on the protein. Moreover, the ability of the 
insulin N-terminus to partially unfold may be critical to bind-
ing in the sterically demanding context of a folded protein. 
The singular connection of the terminal residue to the pro-
tein, like the end of a ball of string, facilitates the adoption of 
a fully solvent-exposed, random-coil structure, akin to short 
peptides. This result is likely not unique to insulin because 
protein termini are typically solvent-exposed, more so than 
charge alone would predict.26 
 
  
 
Figure 3. Crystal structure of the Q7•1 complex. (a) Asymmetric unit of the crystal, with the two molecules of insulin, 1a (green) and 
1b (black), rendered as ribbons and the associated Q7 as sticks. The solvent-accessible surface is shown as semi-transparent to 
reveal the overall shape of the complex. The PheB1 position of 1a, which is bound inside Q7, is rendered as space-filling, with carbon 
in green, oxygen in red, and nitrogen in blue; the N-terminal nitrogen is the blue sphere. (b) Superposition of the two insulins illus-
trates the strong homology between 1a and 1b with clear divergence at the N-terminus of the B-chain. In this image, the PheB1 posi-
tion of both insulins is rendered as space-filling for comparison. 
 
 
Figure 4. Fluorescent indicator displacement assay for insulin. 
(a) Decrease in emission intensity upon titrating insulin at 0, 
0.5, 1.0, 2.0, 4.0, 8.0, and 16.0 M into a mixture of Q7 (6 M) 
and acridine orange (8 M).  (b) Fluorescence quenching for a 
series of proteins and peptides at 4 M in a mixture of 4 M Q7 
and 6 M acridine orange, showing selective binding of native 
insulin 1 and positive control peptide 3. Error bars are standard 
deviatations from at least three measurements. BSA, bovine 
serum albumin; IgG, immunoglobulin G; BCA, bovine carbonic 
anhydrase; GGG, peptide Gly-Gly-Gly. 
Based on the mechanism of binding established here, we 
expected that Q7 would not exhibit high affinity binding to 
proteins lacking an N-terminal aromatic residue. A fluores-
cence indicator displacement assay27 was used to test this 
hypothesis. We chose acridine orange because it has rela-
tively little nonspecific association with proteins, it is effec-
tive at neutral pH, and its Ka value for Q7 (2.0 x 105 M-1) is 
similar yet lower than that of insulin.28 The emission of acri-
dine orange increases when bound to Q7. Therefore, upon 
introducing a competitive analyte to a solution containing 
the Q7•acridine orange complex, the displacement of acri-
dine orange from Q7 yields a decrease in fluorescence in-
tensity that indicates the binding of analyte (Figure 4a). 
The fluorescence response for insulin was compared to 
compounds 2-5, the peptide Gly-Gly-Gly, and a series of 
commercially available blood proteins, including bovine se-
rum albumin (BSA), human immunoglobulin G (IgG), and 
bovine carbonic anhydrase (BCA) (Figure 4b). We observed 
substantial quenching (55-80%) with insulin 1 and peptide 3 
(positive control), but insignificant quenching for the other 
analytes (1-5%), which lack an aromatic terminus. This re-
sult demonstrates that a single residue can enable the se-
lective binding of insulin versus other proteins by at least 
50-100-fold in Ka29 under the conditions used in this study. 
We note explicitly, however, that insulin recognition in vivo 
would be precluded by (i) its relatively high dissociation 
constant (0.67 M) compared to the sub-nM concentrations 
of insulin in blood and saliva, (ii) the presence of weak bind-
ing proteins (e.g., albumin) at sufficiently high concentra-
tions to effectively compete for binding,30-32 and (iii) the pos-
sibility of competition by other peptides and proteins with N-
terminal aromatic groups. This paper does not claim to ad-
dress these challenges pertaining to in vivo applications. 
This paper describes an approach to protein recognition 
that exploits the unique properties of a protein terminus to 
achieve single-site binding that is predictable from the se-
quence of amino acids. Unlike small molecules that bind 
inside protein cavities,5 and unlike natural and synthetic 
receptors that bind to large areas on the surfaces of pro-
 teins,4 Q7 binds to insulin by incorporating the terminal resi-
due within its cavity. When the terminus unravels from the 
surface it becomes fully solvent exposed, thus allowing Q7 
to bind to insulin in the same manner as to a short peptide. 
This motif is extraordinarily minimal, comprising a small and 
structurally simple receptor, a single amino acid residue, 
and a binding interface of ~200 Å2. This approach to protein 
recognition differs from existing methods, such as genetical-
ly engineering polyhistidine (His-tag) or glutathione S-
transferase (GST) fusion proteins into target proteins for 
affinity chromatography,33 or chemically modifying proteins 
with biotin or aminomethylferrocene groups for capture us-
ing avidin or Q7,34-36 respectively. In the current study, Q7 
binds directly to the native protein sequence, not an engi-
neered or chemically modified sequence,37 although we 
consider these techniques to be complementary. We be-
lieve this approach will facilitate the design of receptors for 
other proteins as well as the development of techniques for 
single-site labeling of proteins and for sensing and separat-
ing proteins according to the identity of the terminal residue. 
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